Chondrocurarine (Bisbenzylisoquinoline · Neuromuscular Blocker · Curare Reference)
| Compound | Chondrocurarine (d-Chondrocurarine; Tubocurarine congener) |
| Class | Alkaloid — Bisbenzylisoquinoline (BBIQ) |
| CAS | Not universally assigned; close structural congener of tubocurarine |
| Molecular formula | C₃₇H₄₀N₂O₆ (approximate; varies by specific structural assignment) |
| Primary sources | Chondrodendron tomentosum (curare vine) |
| Plant part | Bark |
| Claim strength | Emerging |
| Key applications | Neuromuscular blocker reference; curare alkaloid pharmacology; respiratory paralysis risk; informational-only |
| Buy from Herbuno | Informational reference — see HerbIQ Compound Index → |
Name origin: Chondrocurarine combines "Chondro-" (from Chondrodendron, the source genus) and "curarine" (denoting curare-type neuromuscular blocking alkaloids). It is a close structural congener of d-tubocurarine — the principal Chondrodendron alkaloid — differing in methylation pattern and/or stereochemistry at the quaternary nitrogen centres. Traditional use: Chondrocurarine is not independently utilised in traditional medicine — it is a constituent of the total Chondrodendron tomentosum alkaloid extract (curare) alongside tubocurarine and isochondodendrine. The therapeutic and toxicological significance of the whole curare preparation is attributed primarily to tubocurarine; chondrocurarine is a pharmacological context compound. Research trajectory: Chondrocurarine was characterised in classical alkaloid chemistry as part of the complete structural inventory of Chondrodendron alkaloids — a necessary step in establishing the SAR basis for synthetic NMBA development. Safety context: All tubocurarine-type BBIQs cause neuromuscular blockade and respiratory paralysis at pharmacologically active doses. Chondrocurarine is not a supplement, food, or cosmetic ingredient.
Pharmacological Profile of Chondrocurarine
Neuromuscular blocking activity: Chondrocurarine produces competitive nAChR antagonism at the neuromuscular junction comparable in mechanism to tubocurarine. Its potency relative to tubocurarine depends on the specific structural variant; quaternary ammonium tubocurarine-type BBIQs generally have higher affinity than tertiary amine congeners due to cationic electrostatic interaction with the anionic receptor binding site. Claim strength: Emerging.
Respiratory paralysis risk: At sufficient systemic concentrations, chondrocurarine and all tubocurarine-type BBIQs cause diaphragmatic paralysis and respiratory arrest. In traditional curare arrow poison use, this was the mechanism of prey immobilisation and death. In pharmaceutical anaesthesia, NMBA-induced respiratory paralysis is managed by mechanical ventilation; reversal agents (neostigmine, sugammadex) restore neuromuscular function. Claim strength: High (pharmacological).
Cardiovascular effects: Tubocurarine-type BBIQs can release histamine (causing hypotension, bronchospasm) and block autonomic ganglia at clinical doses. These effects were major limitations of d-tubocurarine in anaesthesia — leading to the development of steroid-based NMBAs (pancuronium, vecuronium) with fewer cardiovascular side effects. Chondrocurarine's histamine-releasing and ganglionic blocking activities parallel tubocurarine. Claim strength: Moderate (pharmacological).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Chondrocurarine
How does chondrocurarine differ from tubocurarine?
Both are bisbenzylisoquinoline alkaloids from Chondrodendron tomentosum with neuromuscular blocking activity via competitive nAChR antagonism. The structural distinctions lie in methylation pattern at the nitrogen atoms and possibly stereochemistry — chondrocurarine represents one of several tubocurarine-related alkaloids in the Chondrodendron extract. Tubocurarine is the most pharmacologically potent and best characterised; chondrocurarine's independent potency data are limited.
What replaced tubocurarine in modern anaesthesia?
d-Tubocurarine was replaced by a progression of synthetic NMBAs with improved safety profiles: pancuronium (1960s — longer duration, less histamine release), vecuronium and atracurium (1980s — intermediate duration, atracurium's Hofmann elimination enabling renal/hepatic disease use), rocuronium (1990s — rapid onset for RSI), cisatracurium (1990s — less laudanosine production than atracurium), and sugammadex (2000s — selective binding reversal agent specifically for rocuronium/vecuronium). Each represented pharmacological improvements over the natural product template.
Is chondrocurarine relevant to any current pharmaceutical research?
Not directly — its role was as a structural reference point in historical NMBA SAR studies. Current NMBA research focuses on refinement of synthetic frameworks (ultra-short acting NMBAs, optimised reversal agents) rather than returning to natural BBIQ templates. The Chondrodendron alkaloid series has historical scientific importance rather than current pharmaceutical development relevance.
Can tubocurarine or chondrocurarine be administered orally for any effect?
No — quaternary ammonium BBIQs like tubocurarine are not absorbed from the GI tract due to their permanent positive charges preventing membrane permeation. Oral administration of tubocurarine produces no systemic neuromuscular effect; this is the pharmacological basis for the traditional safety of eating curare-killed game and for the inability of any orally consumed BBIQ to produce the parenteral neuromuscular block seen with injection.
Related compounds: Isochondodendrine, Thalidasine, Tetrandrine, Fangchinoline
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery